{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+Emission+tomography", "query": { "intervention": "Positron Emission tomography" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 2325, "total_pages": 233, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+Emission+tomography&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T12:22:35.818Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01937117", "title": "Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Positron emission tomography (PET)", "type": "PROCEDURE" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2014-01-30", "completion_date": "2027-06", "has_results": true, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-09-24T12:22:35.818Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Indianapolis, Indiana + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01937117" }, { "nct_id": "NCT07025369", "title": "Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma", "Stage IIC Prostate Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Flotufolastat F-18 Gallium", "type": "OTHER" }, { "name": "Laparoscopic Radical Prostatectomy with Robotics", "type": "PROCEDURE" }, { "name": "Pelvic Lymphadenectomy", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Relugolix", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 30, "start_date": "2025-08-25", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-09-24T12:22:35.818Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07025369" }, { "nct_id": "NCT03275974", "title": "Glutamine PET Imaging Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "RAS Wild Type", "Stage IV Colorectal Cancer", "Stage IVA Colorectal Cancer", "Stage IVB Colorectal Cancer" ], "interventions": [ { "name": "Carbon C 11 Glutamine", "type": "BIOLOGICAL" }, { "name": "Fluorine F 18 L-glutamate Derivative BAY94-9392", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Blood Draw", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-04-27", "completion_date": "2025-12-23", "has_results": false, "last_update_posted_date": "2026-01-02", "last_synced_at": "2026-09-24T12:22:35.818Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03275974" }, { "nct_id": "NCT01788280", "title": "Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme (GBM)" ], "interventions": [ { "name": "Fluciclitite , PET imaging, and Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-01", "completion_date": "2022-01", "has_results": false, "last_update_posted_date": "2018-02-07", "last_synced_at": "2026-09-24T12:22:35.818Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01788280" }, { "nct_id": "NCT04236986", "title": "Imaging the Neuroimmune System in PTSD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Post Traumatic Stress Disorder" ], "interventions": [ { "name": "Lipopolysaccharide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 34, "start_date": "2017-03-28", "completion_date": "2023-05-30", "has_results": true, "last_update_posted_date": "2024-12-09", "last_synced_at": "2026-09-24T12:22:35.818Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04236986" }, { "nct_id": "NCT01947023", "title": "Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Thyroid Gland Carcinoma", "Unresectable Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Lapatinib", "type": "DRUG" }, { "name": "Lapatinib Ditosylate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2013-09-27", "completion_date": "2027-05-12", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-09-24T12:22:35.818Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01947023" }, { "nct_id": "NCT04199741", "title": "PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Small Cell Lung Carcinoma" ], "interventions": [ { "name": "89Zr-DFO-SC16.56", "type": "DRUG" }, { "name": "SC16.56, Phase I, Cohort 2", "type": "DRUG" }, { "name": "SC16.56, Phase I, Cohort 3", "type": "DRUG" }, { "name": "SC16.56, Phase II", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2019-12-11", "completion_date": "2027-06-11", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-24T12:22:35.818Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04199741" }, { "nct_id": "NCT02673151", "title": "68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Prostate Adenocarcinoma", "PSA Failure", "Recurrent Prostate Carcinoma" ], "interventions": [ { "name": "Computed Tomography (CT) scan", "type": "PROCEDURE" }, { "name": "68Ga-PSMA-11", "type": "DRUG" }, { "name": "Positron Emission Tomography (PET)", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Andrei Iagaru", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 61, "start_date": "2017-05-20", "completion_date": "2019-04-27", "has_results": true, "last_update_posted_date": "2022-01-13", "last_synced_at": "2026-09-24T12:22:35.818Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02673151" }, { "nct_id": "NCT04861077", "title": "Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "[18F]FMISO-PET with contrast-enhanced MRI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "18 Years to 75 Years · Female only" }, "enrollment_count": 20, "start_date": "2027-06", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-09-24T12:22:35.818Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04861077" }, { "nct_id": "NCT07783581", "title": "Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Oral Cavity Squamous Cell Carcinoma", "Locally Recurrent Oral Cavity Squamous Cell Carcinoma", "Oral Cavity Squamous Cell Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Photon Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Spatially-fractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "RADIATION" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-09-07", "completion_date": "2030-04-01", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-24T12:22:35.818Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07783581" } ] }